BEIGENE-BGB-11417-103
Phase I/II
OPEN TO ACCRUAL
A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients with Myeloid Malignancies
BMS-CA0561060
Phase III
OPEN TO ACCRUAL *
A Phase 3b, Open-Label Study Evaluating the Efficacy and Safety of Luspatercept (BMS-986346/ACE-536) Initiated at Maximum Approved Dose in LR-MDS with IPSS-R Very Low-, Low-, or Intermediate-Risk Who Require RBC Transfusions (MAXILUS)
UAB-19113-NTX-301
Phase I
OPEN TO ACCRUAL
A Phase 1 Study of NTX-301, an Oral DNMT1 Inhibitor, in Patients with MDS and AML